Compare Medpace Holdings Inc (MEDP) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Weibo Corp — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: Medpace Holdings Inc is far larger — about 10.8× Weibo Corp's market cap, and Weibo Corp pays a 9.47% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Weibo Corp for 102 Days on average.
| MEDP | WB | |
|---|---|---|
Market Cap | $16.82B | $1.56B |
Volume | 223,093 | 812,503 |
Sector | Health | Media |
52-Week High | $630.19 | $12.37 |
52-Week Low | $393.42 | $6.33 |
Typical Hold Time | 14 Days | 102 Days |
Enterprise Value | $16.44B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Weibo (WB) trades at $6.55, up 1.08% with bearish technical indicators but attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported Q2 2026 earnings beat with $449M net income in 2025, though recent quarters show mixed results. Cash flow trends show volatility with a $694M net outflow in 2024, while analyst sentiment remains divided with 40.9% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with strong profitability margins but faces significant headwinds from declining user metrics and advertising challenges. The stock's low valuation multiples suggest potential upside if operational stability improves, though competitive pressures and China's regulatory environment remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
